Could less hormone therapy be enough for High-Risk prostate cancer?
NCT ID NCT05100472
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether a shorter course of hormone therapy (6 months instead of the usual longer duration) combined with targeted radiation can safely prevent high-risk prostate cancer from spreading. About 50 men with aggressive prostate cancer will receive hormone therapy, followed by brachytherapy and external beam radiation. The goal is to maintain cancer control while reducing side effects from hormones.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Androgen deprivation therapy (bicalutamide and leuprolide) plus brachytherapy and external beam radiation
What this could lead to
If successful, this could offer a way to treat high-risk prostate cancer with fewer hormone therapy side effects while still preventing the cancer from spreading.
What could go wrong
This is a small, early-phase trial (50 people) with no control group, so results may not apply broadly. The shorter hormone course might be less effective at preventing recurrence.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, 10065, United States
-
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
Uniondale, New York, 11553, United States
-
Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
Harrison, New York, 10604, United States